Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004)
机构：[1]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China[2]Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China[3]Inner Mongolia Autonomous Reg Peoples Hosp, Dept Med Oncol, Hohhot, Peoples R China[4]First Hosp Shijiazhuang, Shijiazhuang, Hebei, Peoples R China[5]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China河北大学附属医院
第一作者机构：[1]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
推荐引用方式(GB/T 7714)：
Huang Dingzhi,Zhong Diansheng,Zhang Cuiying,et al.Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004)[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(15):
APA：
Huang, Dingzhi,Zhong, Diansheng,Zhang, Cuiying,Zhang, Yan,Shang, Yanhong&Wang, Liuchun.(2020).Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).JOURNAL OF CLINICAL ONCOLOGY,38,(15)
MLA：
Huang, Dingzhi,et al."Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004)".JOURNAL OF CLINICAL ONCOLOGY 38..15(2020)
医学